{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:13:17Z","timestamp":1763727197388,"version":"3.40.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.amjcard.2017.07.096","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T16:23:00Z","timestamp":1502209380000},"page":"1830-1836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Meta-Analysis of Safety and Efficacy of Uninterrupted Non\u2013Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists for Catheter Ablation of Atrial Fibrillation"],"prefix":"10.1016","volume":"120","author":[{"given":"Akram Y.","family":"Elgendy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhruv","family":"Mahtta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6859-4616","authenticated-orcid":false,"given":"Amr F.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abuzaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amgad","family":"Mentias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed N.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam Y.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.07.096_bib0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.hrthm.2011.12.016","volume":"9","author":"Calkins","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0015","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0020","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE Expert consensus statement on catheter and surgical ablation of atrial fibrillation","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0030","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","article-title":"Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry","volume":"63","author":"Lakkireddy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCEP.114.001586","article-title":"Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures","volume":"7","author":"Dillier","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0040","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jce.12143","article-title":"Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation","volume":"24","author":"Maddox","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10840-012-9719-9","article-title":"Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin","volume":"35","author":"Konduru","year":"2012","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10840-016-0221-7","volume":"48","author":"Zhao","year":"2017","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10840-016-0195-5","article-title":"Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation","volume":"48","author":"Ukaigwe","year":"2017","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0060","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.cjca.2015.09.012","article-title":"Uninterrupted new oral anticoagulants compared with uninterrupted vitamin K antagonists in ablation of atrial fibrillation: a meta-analysis","volume":"32","author":"Nairooz","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0065","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"RE-CIRCUIT Investigators: uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0070","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jce.12928","article-title":"Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study","volume":"27","author":"Kuwahara","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jjcc.2016.03.014","article-title":"Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation","volume":"69","author":"Yoshimura","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0080","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1253\/circj.CJ-16-0621","article-title":"Efficacy and safety of rivaroxaban and warfarin in the perioperative period of catheter ablation for atrial fibrillation\u2014outcome analysis from a prospective multicenter registry study in Japan","volume":"80","author":"Okumura","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0085","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0095","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0100","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0115","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10840-016-0214-6","article-title":"Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin","volume":"48","author":"Tao","year":"2017","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0125","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","article-title":"Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study","volume":"12","author":"Di Biase","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2014.10.005","article-title":"Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias undercontinuous anticoagulation with apixaban versus phenprocoumon","volume":"115","author":"Kaess","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0135","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.hrthm.2015.04.016","article-title":"Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation","volume":"12","author":"Nagao","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0140","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.07.096_bib0145","first-page":"35","article-title":"Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab","volume":"12","author":"Hu","year":"2016","journal-title":"Vasc Health Risk Manag"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917313024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917313024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T09:32:05Z","timestamp":1582536725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917313024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0002914917313024"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.096","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis of Safety and Efficacy of Uninterrupted Non\u2013Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists for Catheter Ablation of Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}